智飞生物：全资子公司获得药物临床试验批准通知书

Group 1 - The core point of the article is that Zhifei Biological (SZ 300122) has received approval from the National Medical Products Administration for clinical trials of its acellular combined vaccine for diphtheria, tetanus, and pertussis aimed at adolescents and adults [1] - Zhifei Biological's revenue composition for the year 2024 is projected to be 99.14% from biological products and 0.86% from other businesses [1] - As of the report, Zhifei Biological has a market capitalization of 52.1 billion yuan [1] Group 2 - The chairman of Peking University Pharmaceutical, Xu Xiren, was investigated by the police prior to his arrest, with reports indicating that the group's assets were disposed of and large sums of money are unaccounted for [1]